Human granulocytic anaplasmosis and Anaplasma phagocytophilum

Emerging Infectious Diseases

Volumn 11, Issue 12, 2005, Pages 1828-1834

  Dumler, J Stephen ^a,d   Choi, Kyoung Seong ^a   Garcia Garcia, Jose Carlos ^a   Barat, Nicole S ^a   Scorpio, Diana G ^a   Garyu, Justin W ^a   Grab, Dennis J ^a   Bakken, Johan S ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA DULUTH   (United States)

^c St Luke's Hospital   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; ANAPLASMA PHAGOCYTOPHILUM; ANAPLASMOSIS; CLINICAL FEATURE; DISEASE SEVERITY; EUROPE; GRANULOCYTE; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOLOGY; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; UNITED STATES;

EID: 33644836153     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1112.050898     Document Type: Review

References (40)

1. Chen S-M, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol. 1994;32:589-95.
2. Bakken JS, Dumler JS, Chen SM, Eckman MR, Van Etta LL, Walker DH. Human granulocytic ehrlichiosis in the upper midwest United States. A new species emerging? JAMA. 1994;272:212-8.
3. Dumler JS, Barbet AF, Bekker CP, Dasch GA, Palmer GH, Ray SC, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol. 2001;51:2145-65.
4. Walker DH, Dumler JS. Emergence of ehrlichioses as human health problems. Emerg Infect Dis. 1996;2:18-29.
5. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA. 1996;275:199-205.
6. Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, McKenna DF, Nowakowski J, Munoz J, et al. Human granulocytic ehrlichiosis (HGE): a case series from a single medical center in New York State. Ann Intern Med.1996;125:904-8.
7. Hardalo C, Quagliarello V, Dumler JS. Human granulocytic ehrlichiosis in Connecticut: report of a fatal cases. Clin Infect Dis. 1995;21:910-4.
8. Lotric-Furlan S, Petrovec M, Avsic-Zupanc T, Strle F. Human granulocytic ehrlichiosis in Slovenia. Ann N Y Acad Sci. 2003;990:279-84.
9. Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in Europe. Clin Microbiol Infect. 2002;8:763-72.
10. Bjoersdorff A, Wittesjo B, Berglun J, Massung RF, Eliasson I. Human granulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden: report from a prospective clinical study. Scand J Infect Dis. 2002;34:187-91.
11. Belongia EA, Gale CM, Reed KD, Mitchell PD, Vandermause M, Finkel MF, et al. Population-based incidence of human granulocytic ehrlichiosis in northwestern Wisconsin, 1997-1999. J Infect Dis. 2001;184:1470-4.
12. Belongia EA, Reed KD, Mitchell PD, Chyou PH, Mueller-Rizner N, Finkel MF, et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis. 1999;29:1472-7.
13. Wallace BJ, Brady G, Ackman DM, Wong SJ, Jacquette G, Lloyd EE, et al. Human granulocytic ehrlichiosis in New York. Arch Intern Med. 1998;158:769-73.
14. Lotric-Furlan S, Petrovec M, Avsic-Zupanc T, Strle F. Comparison of patients fulfilling criteria for confirmed and probable human granulocytic ehrlichiosis. Scand J Infect Dis. 2004;36:817-22.
15. Bakken JS. Clinical diagnosis and treatment of human granulocytic anaplasmosis. In: Abstracts of the 4th International Conference on Rickettsiae and Rickettsial Diseases, Logrono, Spain, 2005 Jun 18-21. Abstract O-34.
16. Bakken JS, Goellner P, Van Etten M, Boyle DZ, Swonger OL, Mattson S, et al. Seroprevalence of human granulocytic ehrlichiosis (HGE) and risk factors associated with infection among residents in northwestern Wisconsin. Clin Infect Dis. 1998;27:1491-6.
17. Aguero-Rosenfeld ME, Donnarumma L, Zentmaier L, Jacob J, Frey M, Noto R, et al. Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol. 2002;40:2612-5.
18. IJdo JW, Meek JI, Cartter ML, Magnarelli LA, Wu C, Tenuta SW, et al. The emergence of another tickborne infection in the 12-town area around Lyme, Connecticut: human granulocytic ehrlichiosis. J Infect Dis. 2000;181:1388-93.
19. Lepidi H, Bunnell JE, Martin ME, Madigan JE, Stuen S, Dumler JS. Comparative pathology and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg. 2000;62:29-37.
20. Brodie TA, Holmes PH, Urquhart GM. Some aspects of tick-borne diseases of British sheep. Vet Rec. 1986;118:415-8.
21. Gribble DH. Equine ehrlichiosis. J Am Vet Med Assoc. 1969;155:462-9.
22. Lin M, Rikihisa Y. Ehrlichia chaffeensis and Anaplasma phagocytophilum lack genes for lipid A biosynthesis and incorporate cholesterol for their survival. Infect Immun. 2003;71:5324-31.
23. Ohashi N, Zhi N, Lin Q, Rikihisa Y. Characterization and transcriptional analysis of gene clusters for a type IV secretion machinery in human granulocytic and monocytic ehrlichiosis agents. Infect Immun. 2002;70:2128-38.
24. Caturegli P, Asanovich KM, Walls JJ, Bakken JS, Madigan JE, Popov S, et al. ankA: an Ehrlichia phagocytophila group gene encoding a protein antigen with ankyrin-like repeats. Infect Immun. 2000;68:5277-83.
25. Herron MJ, Nelson CM, Larson J, Snapp KR, Kansas GS, Goodman JL. Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. Science. 2000;288:1653-6.
26. Park J, Choi K-S, Dumler JS. Major surface protein 2 (Msp2) of Anaplasma phagocytophilum facilitates adherence to granulocytes. Infect Immun. 2003;71:4018-25.
27. Webster P, IJdo JW, Chicoine LM, Fikrig E. The agent of human granulocytic ehrlichiosis resides in an endosomal compartment. J Clin Invest. 1998;101:1932-41.
28. Scorpio DG, Caspersen K, Ogata H, Park J, Dumler JS. Restricted changes in major surface protein-2 (msp2) transcription after prolonged in vitro passage of Anaplasma phagocytophilum. BMC Microbiol. 2004;4:1.
29. Park J, Kim KJ, Choi KS, Grab DJ, Dumler JS. Anaplasma phagocytophilum AnkA binds to granulocyte DNA and nuclear proteins. Cell Microbiol. 2004;6:743-51.
30. Dumler JS, Trigiani ER, Bakken JS, Aguero-Rosenfeld ME, Wormser GP. Serum cytokine responses during acute human granulocytic ehrlichiosis. Clin Diagn Lab Immunol. 2000;7:6-8.
31. Martin ME, Caspersen K, Dumler JS. Immunopathology and ehrlichial propagation are regulated by interferon gamma (IFN?) and interleukin-10 (IL-10) in a murine model of human granulocytic ehrlichiosis (HGE). Am J Pathol. 2001;158:1881-8.
32. Klein MB, Hu S, Chao CC, Goodman JL. The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. J Infect Dis. 2000;182:200-5.
33. Akkoyunlu M, Malawista SE, Anguita J, Fikrig E. Exploitation of interleukin-8-induced neutrophil chemotaxis by the agent of human granulocytic ehrlichiosis. Infect Immun. 2001;69:5577-88.
34. Carlyon JA, Abdel-Latif D, Pypaert M, Lacy P, Fikrig E. Anaplasma phagocytophilum utilizes multiple host evasion mechanisms to thwart NADPH oxidase-mediated killing during neutrophil infection. Infect Immun. 2004;72:4772-83.
35. Carlyon JA, Chan WT, Galan J, Roos D, Fikrig E. Repression of rac2 mRNA expression by Anaplasma phagocytophila is essential to the inhibition of superoxide production and bacterial proliferation. J Immunol. 2002;169:7009-18.
36. Choi K-S, Dumler JS. Early induction and late abrogation of respiratory burst in A. phagocytophilum-infected neutrophils. Ann N Y Acad Sci. 2003;990:488-93.
37. Ge Y, Yoshiie K, Kuribayashi F, Lin M, Rikihisa Y. Anaplasma phagocytophilum inhibits human neutrophil apoptosis via upregulation of bfl-1, maintenance of mitochondrial membrane potential and prevention of caspase 3 activation. Cell Microbiol. 2005;7:29-38.
38. Choi K-S, Garyu J, Park J, Dumler JS. Diminished adhesion of Anaplasma phagocytophilum-infected neutrophils to endothelial cells is associated with reduced leukocyte surface selectin expression. Infect Immun. 2003;71:4586-94.
39. Choi KS, Grab DJ, Dumler JS. Anaplasma phagocytophilum infection induces protracted neutrophil degranulation. Infect Immun. 2004;72:3680-3.
40. Garyu JW, Choi KS, Grab DJ, Dumler JS. Defective phagocytosis in Anaplasma phagocytophilum-infected neutrophils. Infect Immun. 2005;73:1187-90.